SCHEMBL6243239

SCHEMBL6243239

COC(=O)C(=O)C(c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.50
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
CES1 P23141 2/20 0.42
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4369552 0.82 KCNN4 (0.57) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL25401154 0.78 KCNN4 (0.52) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL14354433 0.77 MAPT (0.50) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL14881144 0.77 KCNN4 (0.50) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL6016877 0.74 MAPT (0.63) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL8995888 0.72 KCNN4 (0.53) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL18650576 0.72 CES1 (0.53) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL27508980 0.71 KCNN4 (0.62) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL3534906 0.70 KCNN4 (0.47) KCNN4HDAC3HDAC4HDAC1HDAC7
SCHEMBL18339128 0.70 MAPT (0.48) KCNN4HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1582201-B1 Use of asymmetrically substituted triazine derivatives for solubilising or for enhancing the solubilisation of symmetrically substituted triazine derivatives in oil compositions BEIERSDORF AG (DE) 2013-08-21 EP disclosed
EP-1582201-A2 Use of asymmetrically substituted triazine derivatives for solubilising or for enhancing the solubilisation of symmetrically substituted triazine derivatives in oil compositions Beiersdorf AG (DE) 2005-10-05 EP disclosed
EP-1559413-A2 Stable cosmetic or dermatologic compositions in the form of W/O emulsions containing asymmetrically substituted triazine derivatives Beiersdorf AG (DE) 2005-08-03 EP disclosed
EP-0950397-B1 Use of asymmetrically substituted triazine derivatives for solubilising or for enhancing the solubilizing of symmetrically substituted triazine derivatives BEIERSDORF AG (DE) 2005-07-27 EP disclosed
EP-1071394-B1 USE OF UNSYMMETRICALLY SUBSTITUTED TRIAZINE DERIVATIVES IN COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR MAINTAINING THE UROCANIC ACID STATUS OF THE SKIN BEIERSDORF AG (DE) 2004-07-14 EP disclosed
US-6372199-B1 Use of unsymmetrically substituted triazine derivatives in cosmetic or dermatological preparations for maintaining the urocanic acid status of the skin BEIERSDORF AG (DE) 2002-04-16 US disclosed
EP-0950397-A1 Use of asymmetrically substituted triazine derivatives for solubilising or for enhancing the solubilizing of symmetrically substituted triazine derivatives Beiersdorf Aktiengesellschaft (DE) 1999-10-20 EP disclosed
EP-0950396-A1 Stable cosmetic or dermatologic compositions in the form of W/O emulsions containing asymmetrically substituted triazine derivatives Beiersdorf Aktiengesellschaft (DE) 1999-10-20 EP disclosed